Eikon Therapeutics Inc (EIKN)

NASDAQHealth CareBiotechnologySnapshot 2026-10-15

$7.42-1.59%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Eikon Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient cash to fund operations into second half of 2027	Eikon Therapeutics aims to fund operations into the second half of 2027 with $596M cash.	Intact	cash falls below level needed to fund operations into second half of 2027	Cash and cash equivalents: $143.013M FY2026-Q2; GAAP. Published target: cash sufficient to fund operations into 2H 2027. Target period ends 2027-06-30; this observation covers 2026-Q2. Source date unavailable143,013,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management consistently communicated that cash reserves would fund operations into the second half of 2027. Cash, cash equivalents, and marketable securities decreased from $596.0M in 2026-Q1 to $531.2M in 2026-Q2, reflecting ongoing cash burn but maintaining runway as planned. The trajectory is delivering on the stated cash runway guidance. Delivery assessment Oct 15, 2026
Manage net income losses to sustain operations	A supporting condition in Eikon Therapeutics Inc's published investment case. The stated target is net income losses no worse than -$82.9M next quarter.	Under Pressure	net income losses worsen beyond -$82.9M next quarter	Net income: $-88.409M FY2026-Q2; GAAP. Published target: net income losses no worse than -$82.9M next quarter. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 13, 2026-88,409,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ca6475f8-acfa-4ff3-8a0a-1604183cccfd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 3 quarters. Net losses increased from $83.0M in 2026-Q1 to $88.4M in 2026-Q2, and cash used in operations rose from -$54.5M in 2025-Q1 to -$89.8M in 2026-Q2, reflecting higher R&D spend. Management emphasizes disciplined capital deployment but losses and cash burn remain elevated, indicating limited progress in reducing operating losses so far. Delivery assessment Oct 15, 2026
Control operating losses to manage cash burn	Operating losses are managed but increased from -$71.4M to -$87.3M in 2026-Q1.	Under Pressure	operating losses worsen beyond -$87.3M next quarter	Operating income: $-93.394M FY2026-Q2; GAAP. Published target: operating losses no worse than -$87.3M next quarter. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 13, 2026-93,394,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ca6475f8-acfa-4ff3-8a0a-1604183cccfd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 3 quarters. Net losses increased from $83.0M in 2026-Q1 to $88.4M in 2026-Q2, and cash used in operations rose from -$54.5M in 2025-Q1 to -$89.8M in 2026-Q2, reflecting higher R&D spend. Management emphasizes disciplined capital deployment but losses and cash burn remain elevated, indicating limited progress in reducing operating losses so far. Delivery assessment Oct 15, 2026
Advance product development with clinical progress	The company advances product development with six abstracts at ASCO 2026.	Intact	lack of clinical progress or negative trial results	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-7.08

$-6.66 → $-7.08 · observed estimates

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-6.66	Unavailable	5 / 0
2026-07-25	$-6.66	Unavailable	5 / 0
2026-07-26	$-6.66	Unavailable	5 / 0
2026-07-27	$-6.19	Unavailable	5 / 4
2026-07-28	$-6.66	Unavailable	5 / 0
2026-07-29	$-6.66	Unavailable	5 / 0
2026-07-30	$-6.19	Unavailable	5 / 4
2026-07-31	$-6.66	Unavailable	5 / 0
2026-08-01	$-6.66	Unavailable	5 / 0
2026-08-02	$-6.19	Unavailable	5 / 4
2026-08-03	$-6.19	Unavailable	5 / 4
2026-08-04	$-6.19	Unavailable	5 / 4
2026-08-05	$-6.19	Unavailable	5 / 4
2026-08-06	$-6.66	Unavailable	5 / 0
2026-08-07	$-6.66	Unavailable	5 / 0
2026-08-08	$-6.19	Unavailable	5 / 4
2026-08-09	$-6.19	Unavailable	5 / 4
2026-08-10	$-6.66	Unavailable	5 / 0
2026-08-11	$-6.66	Unavailable	5 / 0
2026-08-12	$-6.66	Unavailable	5 / 0
2026-08-13	$-6.66	Unavailable	5 / 0
2026-08-14	$-6.66	Unavailable	5 / 0
2026-08-15	$-6.66	Unavailable	5 / 0
2026-08-16	$-6.66	Unavailable	5 / 0
2026-08-17	$-6.66	Unavailable	5 / 0
2026-08-18	$-6.66	Unavailable	5 / 0
2026-08-19	$-6.66	Unavailable	5 / 0
2026-08-20	$-6.79	Unavailable	5 / 0
2026-08-21	$-6.79	Unavailable	5 / 0
2026-08-22	$-6.79	Unavailable	5 / 0
2026-08-23	$-6.79	Unavailable	5 / 0
2026-08-24	$-6.79	Unavailable	5 / 0
2026-08-25	$-6.79	Unavailable	5 / 0
2026-08-26	$-6.79	Unavailable	5 / 0
2026-08-27	$-6.79	Unavailable	5 / 0
2026-08-28	$-6.79	Unavailable	5 / 0
2026-08-29	$-6.79	Unavailable	5 / 0
2026-08-30	$-6.79	Unavailable	5 / 0
2026-08-31	$-6.79	Unavailable	5 / 0
2026-09-01	$-6.79	Unavailable	5 / 0
2026-09-02	$-6.79	Unavailable	5 / 0
2026-09-03	$-6.79	Unavailable	5 / 0
2026-09-04	$-6.79	Unavailable	5 / 0
2026-09-05	$-6.79	Unavailable	5 / 0
2026-09-06	$-6.79	Unavailable	5 / 0
2026-09-07	$-6.79	Unavailable	5 / 0
2026-09-08	$-6.79	Unavailable	5 / 0
2026-09-09	$-7.08	Unavailable	5 / 0
2026-09-10	$-7.08	Unavailable	5 / 0
2026-09-11	$-7.08	Unavailable	5 / 0
2026-09-12	$-7.08	Unavailable	5 / 0
2026-09-13	$-7.08	Unavailable	5 / 0
2026-09-14	$-7.08	Unavailable	5 / 0
2026-09-15	$-7.08	Unavailable	5 / 0
2026-09-16	$-7.08	Unavailable	5 / 0
2026-09-17	$-7.08	Unavailable	5 / 0
2026-09-18	$-7.08	Unavailable	5 / 0
2026-09-19	$-7.08	Unavailable	5 / 0
2026-09-20	$-7.08	Unavailable	5 / 0
2026-09-21	$-7.08	Unavailable	5 / 0
2026-09-22	$-7.08	Unavailable	5 / 0
2026-09-23	$-7.08	Unavailable	5 / 0
2026-09-24	$-7.08	Unavailable	5 / 0
2026-09-25	$-7.08	Unavailable	5 / 0
2026-09-26	$-7.08	Unavailable	5 / 0
2026-09-27	$-7.08	Unavailable	5 / 0
2026-09-28	$-7.08	Unavailable	5 / 0
2026-09-29	$-7.08	Unavailable	5 / 0
2026-09-30	$-7.08	Unavailable	5 / 0
2026-10-01	$-7.08	Unavailable	5 / 0
2026-10-02	$-7.08	Unavailable	5 / 0
2026-10-03	$-7.08	Unavailable	5 / 0
2026-10-04	$-7.08	Unavailable	5 / 0
2026-10-05	$-7.08	Unavailable	5 / 0
2026-10-06	$-7.08	Unavailable	5 / 0
2026-10-07	$-7.08	Unavailable	5 / 0
2026-10-08	$-7.08	Unavailable	5 / 0
2026-10-09	$-7.08	Unavailable	5 / 0
2026-10-10	$-7.08	Unavailable	5 / 0
2026-10-11	$-7.08	Unavailable	5 / 0
2026-10-12	$-7.08	Unavailable	5 / 0
2026-10-13	$-7.08	Unavailable	5 / 0
2026-10-14	$-7.08	Unavailable	5 / 0
2026-10-15	$-7.08	Unavailable	5 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	5	1
2026-06-01	5	1
2026-07-01	5	1
2026-08-01	5	1
2026-09-01	5	1
2026-10-01	5	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain sufficient cash to fund operations into second half of 2027Cash and cash equivalents: $143.013M
Manage net income losses to sustain operationsPublished status: Under Pressure
Control operating losses to manage cash burnPublished status: Under Pressure
Advance product development with clinical progressDirect metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.5%Typical daily move · historical

Downside history

-58.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Eikon Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious due to recent earnings misses and elevated cash burn, which raises concerns about future performance.

What's priced into Eikon Therapeutics Inc

The market appears to have priced in a significant level of uncertainty, particularly regarding EIKN's ability to meet future earnings expectations. Given the company's loss-making status and recent financial struggles, expectations may be low compared to peers.

What the fundamentals likely do

Fundamentals are likely to remain under pressure in the near term, as management faces challenges in managing operating losses and cash burn. The recent financial performance has been weak, and there is a high probability of missing earnings expectations again.

What Eikon Therapeutics Inc hinges on

The thesis hinges on several key factors, including the potential for EIKN to advance its oncology pipeline and manage its cash reserves effectively. Additionally, the performance of sector bellwethers and the overall economic environment will play a crucial role in shaping future outcomes.